{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T03:09:52Z","timestamp":1715656192686},"reference-count":0,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Gastroenterology"],"published-print":{"date-parts":[[2001]]},"abstract":"<jats:p>Infection with<jats:italic>Helicobacter pylori<\/jats:italic>is accepted as the primary cause of peptic ulcer disease, and there is evidence to suggest its role in other gastrointestinal disorders. An estimated 20% to 40% of the Canadian population is infected with<jats:italic>H pylori<\/jats:italic>; however, clinically relevant disease is present in only approximately 10% to 20% of these individuals. Therefore, it is crucial to identify the diseases for which eradication of<jats:italic>H pylori<\/jats:italic>is beneficial to ensure that patients do not receive unnecessary treatment. In patients with ulcers induced by long term treatment with nonsteroidal anti-inflammatory drugs, preliminary results suggest that eradication of<jats:italic>H pylori<\/jats:italic>may reduce the risk of peptic ulcer bleeding. Furthermore, a benefit has been observed for the eradication of<jats:italic>H pylori<\/jats:italic>before patients commence therapy with a nonsteroidal anti-inflammatory drug. An association between the presence of<jats:italic>H pylori<\/jats:italic>and specific dyspeptic symptoms has yet to be established; however, there may be a subset of patients with functional dyspepsia who benefit from the eradication of<jats:italic>H pylori<\/jats:italic>. The relationship between gastroesophageal reflux disorder and<jats:italic>H pylori<\/jats:italic>infection remains unclear. In Canada, the recommended therapy for the eradication of<jats:italic>H pylori<\/jats:italic>is seven days of twice-daily treatment with a proton pump inhibitor, clarithromycin, and amoxicillin or metronidazole. Although the proton pump inhibitors are treated as a class for use in these regimens, there is suggestion that a faster onset of action may lead to a higher rate of eradication.<\/jats:p>","DOI":"10.1155\/2001\/279596","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T21:01:15Z","timestamp":1458853275000},"page":"251-255","source":"Crossref","is-referenced-by-count":6,"title":["Update on the Role of<i>H pylori<\/i>Infection in Gastrointestinal Disorders"],"prefix":"10.1155","volume":"15","author":[{"given":"Hugh","family":"Chaun","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","container-title":["Canadian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2001\/279596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2001\/279596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T07:47:10Z","timestamp":1471938430000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/cjgh\/2001\/279596\/abs\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001]]}},"alternative-id":["279596"],"URL":"https:\/\/doi.org\/10.1155\/2001\/279596","relation":{},"ISSN":["0835-7900"],"issn-type":[{"value":"0835-7900","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}